These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8637461)

  • 1. Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee.
    McManus P; Primrose JG; Henry DA; Birkett DJ; Lindner J; Day RO
    Med J Aust; 1996 May; 164(10):589-92. PubMed ID: 8637461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
    Barozzi N; Tett SE
    Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF; Oakley SP; Major GA
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm).
    Vlahovic-Palcevski V; Wettermark B; Bergman U
    Eur J Clin Pharmacol; 2002 Jun; 58(3):209-14. PubMed ID: 12107607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-efficiency of nonsteroidal anti-inflammatory drug prescribing in Zagreb, Croatia.
    Vukusić I; Stimac D; Culig J
    Coll Antropol; 2005 Jun; 29(1):143-7. PubMed ID: 16117313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs.
    May FW; Rowett DS; Gilbert AL; McNeece JI; Hurley E
    Med J Aust; 1999 May; 170(10):471-4. PubMed ID: 10376022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiles of antibacterial drug use in Australia and trends from 1987 to 1989. A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.
    Birkett DJ; Mitchell AS; Godeck A; Grigson T; Cully R; Lee C
    Med J Aust; 1991 Sep; 155(6):410-5. PubMed ID: 1921794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
    Höer A; Gothe H; Schiffhorst G; Sterzel A; Grass U; Häussler B
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):854-8. PubMed ID: 17323403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications.
    Lewis JD; Bilker WB; Brensinger C; Farrar JT; Strom BL
    Am J Gastroenterol; 2002 Oct; 97(10):2540-9. PubMed ID: 12385436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C; Stafford RS; Alexander GC
    Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people.
    Fosbøl EL; Gislason GH; Jacobsen S; Abildstrom SZ; Hansen ML; Schramm TK; Folke F; Sørensen R; Rasmussen JN; Køber L; Madsen M; Torp-Pedersen C
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):822-33. PubMed ID: 18383428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
    Cox ER; Motheral B; Mager D
    Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
    Rahme E; Pettitt D; LeLorier J
    Arthritis Rheum; 2002 Nov; 46(11):3046-54. PubMed ID: 12428249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
    Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland.
    Girvin B; Rafferty T; Stevenson MR; Johnston GD
    Pharmacoepidemiol Drug Saf; 2004 Mar; 13(3):153-7. PubMed ID: 15072114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
    Zandman-Goddard G; Langevitz P
    Harefuah; 2001 Jun; 140(6):476-8, 567, 566. PubMed ID: 11420844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
    Steinfeld S; Bjørke PA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.